Advertisement

Certolizumab

  • Giuseppe Tridente
Chapter

Abstract

Certolizumab-pegol (Cimzia®, UCB) is a recombinant humanized Fab fragment composed of a single light and heavy chain derived from a murine IgG2a antibody, conjugated to polyethylene glycol (PEG2MAL40 K). This Fab, produced in E. Coli and subsequently linked to PEG, is directed to soluble and membrane-bound human TNFα, and inhibits its binding to p55 (TNFR1) and p75 (TNFR2) receptors, but it does not neutralize TNFβ.

Keywords

Rheumatoid Arthritis Tumor Necrosis Factor Rheumatoid Arthritis Patient Optic Neuritis Injection Site Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_14_MOESM1_ESM.xls (75 kb)
Supplementary material 1 (XLS 76 kb)

References

  1. 1.
    Certolizumab-Pegol (Cimzia®) BLA/STN 125160 Resubmission FDA Medical Rev 2008Google Scholar
  2. 2.
    Cimzia® (certolizumab-pegol) EMEA/H/C/740 Refusal Assessment Report 2008Google Scholar
  3. 3.
    Cimzia® (certolizumab-pegol) Prescribing Information. UCB, 2012Google Scholar
  4. 4.
    Connock M, Tubeuf S, Malottki K et al (2009) Certolizumab-Pegol (Cimzia®) for the treatment of rheumatoid arthritis. Evidence Review Group Report commissioned by the NIHR HTA programme on behalf of NICE. Queen’s Printer and controller of HMSO, p 1–112Google Scholar
  5. 5.
    Cimzia® (certolizumab-pegol) EMEA, EPAR Annex I, 2012Google Scholar
  6. 6.
    Tracey D, Klareskob L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther 117:244–279PubMedCrossRefGoogle Scholar
  7. 7.
    Furst DE, Wallis R, Broder M et al (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infections. Semin Arthritis Rheum 36:159–167PubMedCrossRefGoogle Scholar
  8. 8.
    Horiuki T, Mitoma H, Harashima S et al (2010) Transmembrane TNFα: structure, function and interaction with anti-TNF agents. Rheumatology 49:1215–1228CrossRefGoogle Scholar
  9. 9.
    Shu Q, Amin MA, Ruth JH et al (2012) Suppression of endothelial cell activity by inhibition of TNFα. Arthritis Res Ther 14:R88 (1-15)Google Scholar
  10. 10.
    Sandborn WJ, Schreiber S, Feagan BG et al (2011) Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 9:670–678PubMedCrossRefGoogle Scholar
  11. 11.
    Weinblatt ME, Fleischmann R, Huizinga TWJ et al (2012) Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 51:2204–2214PubMedCrossRefGoogle Scholar
  12. 12.
    Keystone EC, Combe B, Smolen J et al (2012) Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology 51:1628–1638PubMedCrossRefGoogle Scholar
  13. 13.
    Choy E, McKenna F, Vencovsky J et al (2012) Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 51:1226–1234PubMedCrossRefGoogle Scholar
  14. 14.
    Ruiz Garcia V, Jobanputra P, Cabello JB et al (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review). Cochrane database of systematic reviews 2011 doi: 10.1002/14651858.CD007649.pub2
  15. 15.
    Bell GM, Reynolds G, Isaacs JD (2011) Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat Rev Rheumatol 7:507–516PubMedCrossRefGoogle Scholar
  16. 16.
    RAPID™ -PsA study showed that certolizumab pegol improved the signs and symptoms of psoriasic arthritis. UCB data file CZP-PRR-013318_052012Google Scholar
  17. 17.
    Reich K, Ortonne J-P, Gottlieb AB et al (2012) Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. BJD 167:180–190CrossRefGoogle Scholar
  18. 18.
    Sfikakis PP (2010) The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. In: Kollias G, Sfikakis PP (eds) TNF pathophysiology. Molecular and cellular mechanisms. Curr Dir Autoimmun 11:180–210Google Scholar
  19. 19.
    Stallmach A, Hagel S, Bruns T (2010) Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 24:167–182PubMedCrossRefGoogle Scholar
  20. 20.
    Rubbert-Roth A (2012) Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 51:38–47. doi: 10.1093/rheumatology/kes114 CrossRefGoogle Scholar
  21. 21.
    Horton SC, Nam JL, Buch MH (2012) Safety of biologics in rheumatoid arthritis. Int J Clin Rheumatol 7:425–451CrossRefGoogle Scholar
  22. 22.
    Stuart ME, Strite SA (2011) Systematic safety review of five biologic antirheumatic drugs. Delfini group p 1–275. (www.delfini.org)

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations